Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Stroke 1Recurrence 1Pulmonary Disease, Chronic Obstructive 1Multiple Myeloma 1Kidney Failure, Chronic 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Hepatocellular 1COVID-19 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × tocilizumab × Clear all
NCT06372574 2024-09-03

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Genentech, Inc.

Phase 1 Withdrawn

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡